



ActoGeniX

newsletter

ActoGeniX extends equity financing round to EUR 15.5 million

Ghent, March 24, 2009 - ActoGeniX announced last February that it had successfully closed an equity financing round of EUR 13.5 million from a broad syndicate of life sciences investors. Today, the Company has extended this round by an additional 2 million from this same investor group, bringing the total amount of the round to EUR 15.5 million (approximately US\$ 20 million).

The current syndicate includes new investor Biovest (Belgium), as well as the existing investors Gimv, Biotech Fund Flanders, Baekeland Fund, VIB (Belgium), LSP, Aescap Venture (the Netherlands) and Ventech (France).

This financing will allow ActoGeniX to timely execute its ongoing and planned clinical development programs and to fund operations until mid-2011, without taking into account potential revenue-generating corporate partnerships. ActoGeniX is well on track with building its product pipeline. Its lead product, **AG011** for inflammatory bowel disease, is currently being tested in a multinational Phase 2 clinical trial in ulcerative colitis patients, with top-line data expected before mid-2009. Within the next week, ActoGeniX plans to file an IND in the US, to start a Phase 1b clinical trial to evaluate its second product, **AG013**, for treatment of oral mucositis in cancer patients.

For more information about ActoGeniX, please visit www.ActoGeniX.com

For further information please contact:

ActoGeniX

Dr Mark Vaeck, CEO - Tel. +32 (0) 9 2610600 - mark.vaeck@actogenix.com

Press contact:

Across

Karolien Waegeman – Mobile +32 (0) 479 98 98 70 – karolien.waegeman@a-cross.com